Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles

Vaccine

Volumn 34, Issue 8, 2016, Pages 1025-1033

  Salverda, Merijn L M ^a   Meinderts, Sanne M ^a,d   Hamstra, Hendrik Jan ^b   Wagemakers, Alex ^c   Hovius, Joppe W R ^c   van der Ark, Arno ^a   Stork, Michiel ^a   van der Ley, Peter ^a  

^a Institute for Translational Vaccinology (Intravacc)   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d SANQUIN RESEARCH   (Netherlands)

Author keywords

Borrelia burgdorferi; FHbp; Heterologous expression; Lipoprotein; Neisseria meningitidis; OMV; OspA; Outer Membrane Vesicles; Surface display

Indexed keywords

BINDING PROTEIN; FACTOR H BINDING PROTEIN; OUTER SURFACE PROTEIN A; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; LIPOPROTEIN; MEMBRANE ANTIGEN; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL OUTER MEMBRANE; CONTROLLED STUDY; FEMALE; FUSION GENE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MEMBRANE VESICLE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BORRELIA BURGDORFERI; IMMUNOLOGY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; FEMALE; LIPOPROTEINS; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS;

EID: 84955250932     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.01.019     Document Type: Article

References (62)

1. Ellis T.N., Kuehn M.J. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev 2010, 74:81-94.
2. Chen D.J., Osterrieder N., Metzger S.M., Buckles E., Doody A.M., DeLisa M.P., et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci USA 2010, 107:3099-3104.
3. Muralinath M., Kuehn M.J., Roland K.L., Curtiss R. Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect Immun 2011, 79:887-894.
4. Alaniz R.C., Deatherage B.L., Lara J.C., Cookson B.T. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol 2007, 179:7692-7701.
5. Gaillard M.E., Bottero D., Errea A. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes. Vaccine 2014, 32:931-937.
6. Zollinger W.D., Donets M.A., Schmiel D.H., Pinto V.B., Labrie J.E., Moran E.E., et al. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 2010, 28:5057-5067.
7. Nieves W., Petersen H., Judy B.M., Blumentritt C.A., Russell-Lodrigue K., Roy C.J., et al. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol 2014, 21:747-754.
8. Camacho A.I., de Souza J., Sanchez-Gomez S., Pardo-Ros M., Irache J.M., Gamazo C. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice. Vaccine 2011, 29:8222-8229.
9. Kim O.Y., Hong B.S., Park K.S., Yoon Y.J., Choi S.J., Lee W.H., et al. Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol 2013, 190:4092-4102.
10. Keenan J.I., Rijpkema S.G., Durrani Z., Roake J.A. Differences in immunogenicity and protection in mice and guinea pigs following intranasal immunization with Helicobacter pylori outer membrane antigens. FEMS Immunol Med Microbiol 2003, 36:199-205.
11. Roberts R., Moreno G., Bottero D., Gaillard M.E., Fingermann M., Graieb A., et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 2008, 26:4639-4646.
12. Bartolini E., Ianni E., Frigimelica E., Petracca R., Galli G., Berlanda Scorza F., et al. Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro. J Extracellular Vesicles 2013, 2:20181. 10.3402/jev.v2i0.20181.
13. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl 2):B3-B12.
14. Nokleby H., Aavitsland P., O'Hallahan J., Feiring B., Tilman S., Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007, 25:3080-3084.
15. Gorringe A.R., Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccine Immunother 2012, 8:174-183.
16. Acevedo R., Fernandez S., Zayas C., Acosta A., Sarmiento M.E., Ferro V.A., et al. Bacterial outer membrane vesicles and vaccine applications. Front Immunol 2014, 5:121.
17. Kesty N.C., Kuehn M.J. Incorporation of heterologous outer membrane and periplasmic proteins into Escherichia coli outer membrane vesicles. J Biol Chem 2004, 279:2069-2076.
18. Fantappie L., de Santis M., Chiarot E., Carboni F., Bensi G., Jousson O., et al. Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen. J Extracellular Vesicles 2014, 3:24015. 10.3402/jev.v3.24015.
19. Schild S., Nelson E.J., Bishop A.L., Camilli A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun 2009, 77:472-484.
20. Kim J.Y., Doody A.M., Chen D.J., Cremona G.H., Shuler M.L., Putnam D., et al. Engineered bacterial outer membrane vesicles with enhanced functionality. J Mol Biol 2008, 380:51-66.
21. Barat S., Willer Y., Rizos K., Claudi B., Maze A., Schemmer A.K., et al. Immunity to intracellular Salmonella depends on surface-associated antigens. PLoS Pathog 2012, 8:e1002966.
22. Daleke-Schermerhorn M.H., Felix T., Soprova Z., Ten Hagen-Jongman C.M., Vikstrom D., Majlessi L., et al. Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach. Appl Environ Microbiol 2014, 80:5854-5865.
23. Galen J.E., Curtiss R. The delicate balance in genetically engineering live vaccines. Vaccine 2014, 32:4376-4385.
24. Hess J., Gentschev I., Miko D., Welzel M., Ladel C., Goebel W., et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci USA 1996, 93:1458-1463.
25. Kang H.Y., Curtiss R. Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol Med Microbiol 2003, 37:99-104.
26. Jong W., Daleke-Schermerhorn M.H., Vikstrom D., Ten Hagen-Jongman C.M., de Punder K., van der Wel N.N., et al. An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. Microb Cell Factories 2014, 13:162.
27. Park M., Sun Q., Liu F., DeLisa M.P., Chen W. Positional assembly of enzymes on bacterial outer membrane vesicles for cascade reactions. PloS one 2014, 9:e97103.
28. Cornelis P. Expressing genes in different Escherichia coli compartments. Curr Opin Biotechnol 2000, 11:450-454.
29. Schroeder J., Aebischer T. Recombinant outer membrane vesicles to augment antigen-specific live vaccine responses. Vaccine 2009, 27:6748-6754.
30. Jong W.S., Sauri A., Luirink J. Extracellular production of recombinant proteins using bacterial autotransporters. Curr Opin Biotechnol 2010, 21:646-652.
31. Jose J., Meyer T.F. The autodisplay story, from discovery to biotechnical and biomedical applications. Microbiol Mol Biol Rev 2007, 71:600-619.
32. Jung H.C., Lebeault J.M., Pan J.G. Surface display of Zymomonas mobilis levansucrase by using the ice-nucleation protein of Pseudomonas syringae. Nat Biotechnol 1998, 16:576-580.
33. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.B., Belisle J.T., Bleharski J.R., et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999, 285:732-736.
34. Thoma-Uszynski S., Stenger S., Takeuchi O., Ochoa M.T., Engele M., Sieling P.A., et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001, 291:1544-1547.
35. Sigal L.H., Zahradnik J.M., Lavin P., Patella S.J., Bryant G., Haselby R., et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med 1998, 339:216-222.
36. Steere A.C., Sikand V.K., Meurice F., Parenti D.L., Fikrig E., Schoen R.T., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998, 339:209-215.
37. Wressnigg N., Barrett P.N., Pollabauer E.M., O'Rourke M., Portsmouth D., Schwendinger M.G., et al. A novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi Sensu Lato. Clin Vaccine Immunol 2014, 21:1490-1499.
38. Comstedt P., Hanner M., Schuler W., Meinke A., Lundberg U. Design and development of a novel vaccine for protection against Lyme borreliosis. PloS one 2014, 9:e113294.
39. Fikrig E., Barthold S.W., Kantor F.S., Flavell R.A. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1990, 250:553-556.
40. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
41. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197:789-799.
42. Koeberling O., Seubert A., Granoff D.M. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 2008, 198:262-270.
43. van de Waterbeemd B., Streefland M., van der Ley P., Zomer B., van Dijken H., Martens D., et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 2010, 28:4810-4816.
44. Okuda S., Tokuda H. Lipoprotein sorting in bacteria. Ann Rev Microbiol 2011, 65:239-259.
45. Steere A.C., Livey I. Lyme disease vaccines. Vaccines 2013, 1122-1132. Saunders Imprint of Elsevier Inc. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
46. van der Ley P., Steeghs L., Hamstra H.J., ten Hove J., Zomer B., van Alphen L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 2001, 69:5981-5990.
47. Bos M.P., Tefsen B., Geurtsen J., Tommassen J. Identification of an outer membrane protein required for the transport of lipopolysaccharide to the bacterial cell surface. Proc Natl Acad Sci USA 2004, 101:9417-9422.
48. Hovius J.W., Hovius K.E., Oei A., Houwers D.J., van Dam A.P. Antibodies against specific proteins of and immobilizing activity against three strains of Borrelia burgdorferi sensu lato can be found in symptomatic but not in infected asymptomatic dogs. J Clin Microbiol 2000, 38:2611-2621.
49. Horton R.M., Hunt H.D., Ho S.N., Pullen J.K., Pease L.R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 1989, 77:61-68.
50. Yang X.F., Pal U., Alani S.M., Fikrig E., Norgard M.V. Essential role for OspA/B in the life cycle of the Lyme disease spirochete. J Exp Med 2004, 199:641-648.
51. Mascioni A., Bentley B.E., Camarda R., Dilts D.A., Fink P., Gusarova V., et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 2009, 284:8738-8746.
52. Li H., Dunn J.J., Luft B.J., Lawson C.L. Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc Natl Acad Sci USA 1997, 94:3584-3589.
53. Oriente F., Scarlato V., Delany I. Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. J Bacteriol 2010, 192:691-701.
54. Chen S., Zuckert W.R. Probing the Borrelia burgdorferi surface lipoprotein secretion pathway using a conditionally folding protein domain. J Bacteriol 2011, 193:6724-6732.
55. Lee J.S., Shin K.S., Pan J.G., Kim C.J. Surface-displayed viral antigens on Salmonella carrier vaccine. Nat Biotechnol 2000, 18:645-648.
56. Rizos K., Lattemann C.T., Bumann D., Meyer T.F., Aebischer T. Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains. Infect Immun 2003, 71:6320-6328.
57. Kovacs-Simon A., Titball R.W., Michell S.L. Lipoproteins of bacterial pathogens. Infect Immun 2011, 79:548-561.
58. Kumru O.S. Surface localization determinants of Borrelia burgdorferi lipoproteins 2011, University of Kansas, Kansas.
59. Schulze R.J., Chen S., Kumru O.S., Zuckert W.R. Translocation of Borrelia burgdorferi surface lipoprotein OspA through the outer membrane requires an unfolded conformation and can initiate at the C-terminus. Mol Microbiol 2010, 76:1266-1278.
60. Schulze R.J., Zuckert W.R. Borrelia burgdorferi lipoproteins are secreted to the outer surface by default. Mol Microbiol 2006, 59:1473-1484.
61. Lee S.J., Liang L., Juarez S., Nanton M.R., Gondwe E.N., Msefula C.L., et al. Identification of a common immune signature in murine and human systemic Salmonellosis. Proc Natl Acad Sci USA 2012, 109:4998-5003.
62. Cote-Sierra J., Bredan A., Toldos C.M., Stijlemans B., Brys L., Cornelis P., et al. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major. Infect Immun 2002, 70:240-248.